Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University, Newcastle, UK.
Ann Rheum Dis. 2011 Jan;70(1):4-7. doi: 10.1136/ard.2010.135376. Epub 2010 Nov 10.
An expanding range of biological therapies is available for patients with rheumatoid arthritis. Clinical trials and real-life experience demonstrate significant interpatient heterogeneity in efficacy as well as important adverse effects of these treatments. In order to maximise their benefit:risk ratios and to minimise later joint damage, we need to define predictors of response and, ideally, of adverse effects for each of these drugs. There is huge interest in this field of 'personalised medicine', which should allow us to optimally match patient with treatment, providing the parallel benefit of reduced treatment costs. In this short article the current state of the art for licensed biological therapies is summarised. There have been some noteworthy discoveries but the challenge is now to design studies to confirm and validate these findings while also devising large, potentially international, collaborations to identify additional, robust biomarkers that predict outcome.
可供类风湿关节炎患者使用的生物疗法范围正在不断扩大。临床试验和实际经验表明，这些治疗方法的疗效存在显著的个体间异质性，同时也存在重要的不良反应。为了最大限度地提高其获益-风险比，并最大程度地减少后期关节损伤，我们需要确定每种药物的反应和（理想情况下）不良反应的预测因素。在这个“个体化医疗”领域存在着巨大的兴趣，这应该使我们能够将患者与治疗最佳匹配，提供降低治疗成本的平行效益。本文简要总结了已获许可的生物疗法的最新技术水平。已经有了一些值得注意的发现，但现在的挑战是设计研究来证实和验证这些发现，同时设计大型的、潜在的国际合作，以确定额外的、稳健的生物标志物来预测结果。
